Metastatic renal cell carcinoma: Current scenario and future trends.
An improved understanding of the biology of renal cell carcinoma (RCC) has led to the development of a number of targeted agents, which has resulted in a paradigm shift in the management of metastatic RCC. We review the current therapeutic strategies for metastatic RCC and present a synopsis of the novel agents in use today with a discussion of the phase III trials that demonstrated their clinical benefit. The management of RCC continues to evolve. The introduction of VEGF and mTOR inhibitors has markedly expanded our drug armamentarium and improved the outcome of a disease that has always been challenging to treat. Knowledge from upcoming trials will help us utilize these drugs for maximum clinical efficacy with optimal dosing and sequencing, either individually or in combination therapy.
Department of Medical Oncology and Hematology, Patel Cancer and Superspeciality Hospital, Jalandhar City, Punjab, India.
Anubha
A
Bharthuar
Mammalian target of rapamycin inhibitor; novel agents; renal cell carcinoma; tyrosine kinase inhibitor; vascular endothelial growth factor inhibitor